Internet-based vestibular rehabilitation versus standard care after acute onset vertigo: a study protocol for a randomized controlled trial.
AVS
Acute onset vertigo
Gait function
Internet-based rehabilitation
Multicenter
Online tool
Portable motion sensors
RCT
Randomized controlled trial
Vestibular rehabilitation
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
16 Jun 2022
16 Jun 2022
Historique:
received:
25
12
2021
accepted:
09
06
2022
entrez:
16
6
2022
pubmed:
17
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Dizziness and vertigo affect around 15% of adults annually and represent common reasons for contacting health services, accounting for around 3% of all emergency department visits worldwide. Vertigo is also associated with excessive use of diagnostic imaging and emergency care and decreased productivity, primarily because of work absenteeism. Vestibular rehabilitation is an evidence-based treatment for chronic dizziness and supervised group exercise therapy has recently been shown to be effective after vestibular neuritis, a common cause of acute onset vertigo. However, such interventions are not readily available and there is a need for more easily accessible tools. The purpose of this study is to investigate the effects on vestibular symptoms of a 6-week online vestibular rehabilitation tool after acute onset vertigo, with the aim of aiding vestibular rehabilitation by presenting a more accessible tool that can help to reduce recovery time. Three hundred twenty individuals diagnosed with acute vestibular syndrome (AVS) will be recruited from multiple hospitals in Sweden and the effects of an online vestibular rehabilitation tool, YrselTräning, on vestibular symptoms after acute onset vertigo will be compared to standard care (written instructions leaflet) in a two-armed, evaluator-blinded, multicenter randomized controlled trial. The primary outcome will be the Vertigo Symptom Scale Short Form (VSS-SF) score at 6 weeks after symptom onset. Secondary outcomes include effects of the intervention on activities of daily living, mood and anxiety, vestibular function recovery, mobility measures, health economic effects, and the reliability of the Swedish VSS-SF translation. Participants using the online vestibular rehabilitation tool are expected to recover earlier and to a greater extent from their symptoms as compared to standard care. Since up to 50% of people with AVS without treatment develop persistent symptoms, effective treatment of AVS will likely lead to a higher quality of life and help reduce the societal costs associated with dizziness and vertigo. Clinicaltrials.gov NCT05056324 . Registered on September 24, 2021.
Sections du résumé
BACKGROUND
BACKGROUND
Dizziness and vertigo affect around 15% of adults annually and represent common reasons for contacting health services, accounting for around 3% of all emergency department visits worldwide. Vertigo is also associated with excessive use of diagnostic imaging and emergency care and decreased productivity, primarily because of work absenteeism. Vestibular rehabilitation is an evidence-based treatment for chronic dizziness and supervised group exercise therapy has recently been shown to be effective after vestibular neuritis, a common cause of acute onset vertigo. However, such interventions are not readily available and there is a need for more easily accessible tools. The purpose of this study is to investigate the effects on vestibular symptoms of a 6-week online vestibular rehabilitation tool after acute onset vertigo, with the aim of aiding vestibular rehabilitation by presenting a more accessible tool that can help to reduce recovery time.
METHODS
METHODS
Three hundred twenty individuals diagnosed with acute vestibular syndrome (AVS) will be recruited from multiple hospitals in Sweden and the effects of an online vestibular rehabilitation tool, YrselTräning, on vestibular symptoms after acute onset vertigo will be compared to standard care (written instructions leaflet) in a two-armed, evaluator-blinded, multicenter randomized controlled trial. The primary outcome will be the Vertigo Symptom Scale Short Form (VSS-SF) score at 6 weeks after symptom onset. Secondary outcomes include effects of the intervention on activities of daily living, mood and anxiety, vestibular function recovery, mobility measures, health economic effects, and the reliability of the Swedish VSS-SF translation.
DISCUSSION
CONCLUSIONS
Participants using the online vestibular rehabilitation tool are expected to recover earlier and to a greater extent from their symptoms as compared to standard care. Since up to 50% of people with AVS without treatment develop persistent symptoms, effective treatment of AVS will likely lead to a higher quality of life and help reduce the societal costs associated with dizziness and vertigo.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov NCT05056324 . Registered on September 24, 2021.
Identifiants
pubmed: 35710448
doi: 10.1186/s13063-022-06460-0
pii: 10.1186/s13063-022-06460-0
pmc: PMC9205069
doi:
Banques de données
ClinicalTrials.gov
['NCT05056324']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
496Subventions
Organisme : Vetenskapsrådet
ID : 2020-00301
Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2012;7(1):e29966
pubmed: 22253839
J Neuroeng Rehabil. 2014 Apr 11;11:58
pubmed: 24725764
Ann Intern Med. 2004 Oct 19;141(8):598-605
pubmed: 15492339
Health Qual Life Outcomes. 2015 Jan 22;13:4
pubmed: 25608680
J Vestib Res. 2008;18(2-3):159-70
pubmed: 19126986
BMC Ear Nose Throat Disord. 2008 Mar 27;8:2
pubmed: 18371190
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Health Econ Rev. 2019 Dec 27;9(1):37
pubmed: 31883042
Ann Fam Med. 2017 May;15(3):209-216
pubmed: 28483885
Mayo Clin Proc. 2008 Jul;83(7):765-75
pubmed: 18613993
Eur Arch Otorhinolaryngol. 2019 Sep;276(9):2389-2396
pubmed: 31098875
Otol Neurotol. 2020 Jan;41(1):78-85
pubmed: 31789800
Qual Life Res. 2014 Mar;23(2):431-42
pubmed: 23975375
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Acad Emerg Med. 2008 Aug;15(8):744-50
pubmed: 18638027
Cochrane Database Syst Rev. 2011 May 11;(5):CD008607
pubmed: 21563170
Sensors (Basel). 2019 Jul 23;19(14):
pubmed: 31340548
Psychosom Med. 2007 Sep-Oct;69(7):700-7
pubmed: 17766688
J Neurol. 2019 Sep;266(Suppl 1):108-117
pubmed: 31286203
Eur Neurol. 2011;66(5):256-63
pubmed: 21986277
BMC Public Health. 2013 Jul 08;13:635
pubmed: 23835212
Eur Neurol. 2018;79(1-2):5-12
pubmed: 29131011
Arch Otolaryngol Head Neck Surg. 1990 Apr;116(4):424-7
pubmed: 2317323
Otol Neurotol. 2018 Dec;39(10):e1111-e1117
pubmed: 30303945
Am J Med. 2017 Dec;130(12):1465.e1-1465.e9
pubmed: 28739195
South Med J. 2000 Feb;93(2):160-7; quiz 168
pubmed: 10701780
Ann Clin Transl Neurol. 2017 Mar 22;4(5):340-346
pubmed: 28491901
BMJ. 2019 Nov 5;367:l5922
pubmed: 31690561